Enanta Pharmaceuticals, Inc. (ENTA)
Automate Your Wheel Strategy on ENTA
With Tiblio's Option Bot, you can configure your own wheel strategy including ENTA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ENTA
- Rev/Share 3.0394
- Book/Share 3.7182
- PB 2.1247
- Debt/Equity 2.6123
- CurrentRatio 4.9992
- ROIC -0.3277
- MktCap 168881120.0
- FreeCF/Share -2.0435
- PFCF -3.8759
- PE -1.8307
- Debt/Assets 0.688
- DivYield 0
- ROE -0.8902
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | ENTA | H.C. Wainwright | -- | Buy | -- | $20 | July 28, 2025 |
News
Enanta Pharmaceuticals, Inc. - Special Call
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Neutral
Enanta Pharmaceuticals, Inc. - Special Call Company Participants Jennifer Viera - Executive Director of Investor Relations & Corporate Communications Jay Luly - President, CEO & Director Scott Rottinghaus - Chief Medical Office Conference Call Participants Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Antonio Arce - WestPark Capital, Inc., Research Division Brian Skorney - Robert W.
Read More
Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change
Published: September 29, 2025 by: Seeking Alpha
Sentiment: Positive
Enanta Pharmaceuticals remains a Buy as zelicapavir shows multiple positive efficacy endpoints in RSV despite missing its primary endpoint in the phase 2b study. Zelicapavir demonstrated statistically significant improvements in PGI-S scores and viral load reduction, supporting potential for phase 3 advancement pending FDA feedback. Strong cash position funds operations into 2028, with ongoing MAVYRET/MAVIRET royalties and a manageable quarterly cash burn.
Read More
Does Enanta Pharmaceuticals (ENTA) Have the Potential to Rally 189.58% as Wall Street Analysts Expect?
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Positive
The consensus price target hints at an 189.6% upside potential for Enanta Pharmaceuticals (ENTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Read More
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Enanta Pharmaceuticals (ENTA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Enanta Pharmaceuticals, Inc. (ENTA)
- IPO Date 2013-03-21
- Website https://www.enanta.com
- Industry Biotechnology
- CEO Jay R. Luly
- Employees 131